|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplement 2. Moderator Analyses** |  |  |  |  |  |  |  |  |  |  |
|  |  | **Suicide Ideation** |  | **Suicide Attempt** |  | **Suicide Death** |
|  |  | **n** | **OR** | **95% CI** | **p** |  | **n** | **OR** | **95% CI** | **p** |  | **n** | **OR** | **95% CI** | **p** |
| **Sample Region** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  **Europe** |  | 2 | - | - | - |  | 25 | 1.03 | (0.98-1.08) | .26 |  | 34 | 1.51 | (1.17-1.95) | .001 |
|  Denmark |  | 0 | - | - | - |  | 0 | - | - | - |  | 14 | 1.51 | (1.08-2.12) | .02 |
|  Finland |  | 0 | - | - | - |  | 7 | 1.68 | (0.80-3.54) | .17 |  | 1 | - | - | - |
|  France |  | 0 | - | - | - |  | 0 | - | - | - |  | 8 | 0.61 | (0.26-1.40) | .24 |
|  Italy |  | 0 | - | - | - |  | 0 | - | - | - |  | 3 | 1.66 | (0.67-4.08) | .27 |
|  Norway |  | 1 | - | - | - |  | 3 | 2.97 | (1.30-6.78) | .01 |  | 0 | - | - | - |
|  Spain |  | 0 | - | - | - |  | 12 | 1.00 | (0.99-1.01) | .75 |  | 2 | - | - | - |
|  Sweden |  | 0 | - | - | - |  | 2 | - | - | - |  | 6 | 2.33 | (1.07-5.10) | .03 |
|  **North America** |  | 21 | 1.21 | (0.73-2.02) | .46 |  | 10 | 3.00 | (1.56-5.77) | <.001 |  | 20 | 1.26 | (0.83-1.90) | .28 |
|  United States |  | 21 | 1.21 | (0.73-2.02) | .46 |  | 9 | 3.79 | (2.28-6.29) | <.001 |  | 19 | 1.15 | (0.81-1.62) | .44 |
|  **Oceania** |  | 0 | - | - | - |  | 14 | 1.16 | (0.90-1.49) | .25 |  | 1 | - | - | - |
|  Australia |  | 0 | - | - | - |  | 13 | 1.15 | (0.89-1.49) | .29 |  | 0 | - | - | - |
| **Sample Type** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  Community |  | 2 | - | - | - |  | 9 | 4.65 | (3.21-6.76) | <.001 |  | 6 | 2.46 | (1.51-4.00) | <.001 |
|  Clinical |  | 21 | 1.21 | (0.73-2.02) | 0.46 |  | 34 | 1.01 | (0.96-1.05) | 0.78 |  | 33 | 1.02 | (0.83-1.24) | 0.86 |
|  Self-injurious |  | 0 | - | - | - |  | 7 | 1.75 | (0.89-3.43) | 0.11 |  | 16 | 2.18 | (1.38-3.44) | <.001 |
| **Diagnostic Criteria** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  **DSM-III** |  | 0 | - | - | - |  | 1 | - | - | - |  | 18 | 1.04 | (0.68-1.58) | .86 |
|  **DSM-III-R** |  | 0 | - | - | - |  | 6 | 0.97 | (0.45-2.10) | .94 |  | 2 | - | - | - |
|  **DSM-IV** |  | 0 | - | - | - |  | 28 | 1.40 | (1.28-1.55) | <.001 |  | 1 | - | - | - |
|  **DSM-IV-TR** |  | 0 | - | - | - |  | 1 | - | - | - |  | 3 | 1.66 | (0.67-4.08) | .27 |
|  **Multiple DSMs** |  | 0 | - | - | - |  | 12 | 1.14 | (0.88-1.49) | .32 |  | 0 | - | - | - |
|  **ICD 10** |  | 0 | - | - | - |  | 0 | - | - | - |  | 3 | 4.02 | (1.77-9.10) | <.001 |
|  **Multiple ICDs** |  | 0 | - | - | - |  | 0 | - | - | - |  | 10 | 1.58 | (1.11-2.24) | .01 |
|  **Research Diagnostic Criteria** |  | 21 | 1.21 | (0.73-2.02) | .46 |  | 0 | - | - | - |  | 9 | 0.73 | (0.35-1.53) | .40 |
|  **Other** |  | 2 | - | - | - |  | 2 | - | - | - |  | 7 | 0.86 | (0.62-1.19) | .35 |
| **Psychiatric Medication** |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
|  **None Medicated** |  | 0 | - | - | - |  | 0 | - | - | - |  | 11 | 0.98 | (0.51-1.88) | .95 |
|  **Some Medicated** |  | 21 | 1.21 | (0.73-2.02) | .46 |  | 16 | 1.18 | (0.93-1.51) | .18 |  | 5 | 2.22 | (1.01-4.86) | .046 |
|  **All Medicated** |  | 2 | - | - | - |  | 2 | - | - | - |  | 0 | - | - | - |
|  **Unspecified** |   | 0 | - | - | - |   | 32 | 1.41 | (1.28-1.55) | <.001 |   | 39 | 1.48 | (1.18-1.87) | <.001 |

*Note*. Samples were categorized as community, clinical, or self-injurious samples based on the reference group. A sample was coded as self-injurious when participants were recruited based on prior self-injurious thoughts and behaviors (e.g., suicide attempt history). Sample was determined as clinical if participants were not selected based on prior self-injurious thoughts and behaviors but based on clinical criteria (e.g., schizophrenia diagnosis). When a sample did not meet the above criteria, it was labeled as a community sample. Moderator analyses of sample type provides a rough estimate of the effects of sample clinical status, and results should be interpreted with caution. Estimates were not reported for analyses involving fewer than three effect sizes as small number of effect sizes reduce the reliability of estimates. Categories that do not have sufficient number of cases across outcomes were omitted from the table (e.g., Canada, New Zealand were omitted from sample region; ICD 8 and 9 were omitted from diagnostic criteria). n = number of effect sizes, OR = weighted mean odds ratio, 95% CI = 95% confidence interval, dashes indicate unavailable information.